PeriimplantitisNCT07379892
Evaluatıon of TREM-1, MMP-8 and TIMP-1 Levels in Perı-Implant Crevicular Fluıd of Perı-Implanted Indıvıduals
An observational study of Periimplantitis, run by Aydin Adnan Menderes University at 1 site in Turkey (Türkiye).
Trial summary
The aim of this study was to evaluate the relationship between Triggering Receptor Expressed on Myeloid Cells-1 (TREM-1), Matrix Metalloproteinases-8 (MMP-8) and Tissue Inhibitors of Metalloproteinases-1 (TIMP-1) levels in peri-implant crevicular fluid (PICF) in peri-implantitis patients. Read more about this study
- Who is it for?
- Ages 18 to 70 yearsHealthy volunteers can take part
- Conditions the study is for
- Periimplantitis
- What is being tested?
- Collection of PICF samples
- How many people
- 54 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 1 Jun 2023to 20 May 2024
- How long will I take part?
- 12 Months
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 70 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: All patients had at least one implant, and this implant had been in place for at least one year since the implant-supported prosthesis was made.
Who may be able to join
- Systemically healthy
- Pregnancy or lactation
Who cannot join
- osteoporosis
- rheumatoid arthritis
- autoimmune disease
- diabetes
Trial locations and contacts
1 site in 1 country.
About this study
The aim of this study was to evaluate the relationship between Triggering Receptor Expressed on Myeloid Cells-1 (TREM-1), Matrix Metalloproteinases-8 (MMP-8) and Tissue Inhibitors of Metalloproteinases-1 (TIMP-1) levels in peri-implant crevicular fluid (PICF) in peri-implantitis patients.
Read the detailed description
The aim of this study was to evaluate the relationship between TREM-1, MMP-8 and TIMP-1 levels in peri-implant crevicular fluid (PICF) in patients with peri-implantitis, and the correlation of these markers with clinical periodontal parameters.
- Conditions
- Periimplantitis
- Being tested
- Collection of PICF samples
- Keywords
- periimplantitis, TREM-1, MMP-8, TIMP-1
- Medical subject headings
- Peri-Implantitis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Collection of PICF samplesOther
TREM-1, MMP-8 and TIPM-1 levels reseach in PICF samples
| Study group | Role | What they receive |
|---|---|---|
| Peri-implantitis | Peri-implantitis is defined as bleeding on probing, suppuration, increased probing depth, clinical attachment loss, and radiographic bone loss Receives: Other: Collection of PICF samples | |
| Peri-implant Health | Peri-implant health is characterized by the absence of bleeding on probing, erythema, swelling, and suppuration in the peri-implant region Receives: Other: Collection of PICF samples |
What is being measured
The primary outcome is the main question the study is designed to answer.
TREM-1, MMP-8 and TIMP-1 levels in PICF samples
TREM-1, MMP-8, and TIMP-1 levels in PICF samples were measured by ELISA method
Measured: 1 month
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 Feb 2026
- Study start1 Jun 2023
- Primary completion15 Dec 2023
- Study completion20 May 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for PeriimplantitisStudies of the same condition, open and under way.
- More trials run by Aydin Adnan Menderes UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Enrolment
- 54 participants (actual)
- Target duration
- 12 Months
Sponsor and investigators
- Lead sponsor
- Aydin Adnan Menderes University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Veli Özgen Öztürk, Aydin Adnan Menderes University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07379892
- Sponsor's protocol ID
- BAP-23003
- Status last verified
- Feb 2026
- First submitted
- 25 Jan 2026
- Last updated
- 9 Feb 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 9 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluatıon of TREM-1, MMP-8 and TIMP-1 Levels in Perı-Implant Crevicular Fluıd of Perı-Implanted Indıvıduals
- ClinicalTrials.gov ID
- NCT07379892
- Acronym / sponsor ID
- BAP-23003
- Conditions
- Periimplantitis
- Keywords
- periimplantitis, TREM-1, MMP-8, TIMP-1
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 54 participants (actual)
- Lead sponsor
- Aydin Adnan Menderes UniversityUniversity, hospital or other
- Study start
- 1 Jun 2023 (actual)
- Primary completion
- 15 Dec 2023 (actual)
- Study completion
- 20 May 2024 (actual)
- First posted
- 2 Feb 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of this study was to evaluate the relationship between Triggering Receptor Expressed on Myeloid Cells-1 (TREM-1), Matrix Metalloproteinases-8 (MMP-8) and Tissue Inhibitors of Metalloproteinases-1 (TIMP-1) levels in peri-implant crevicular fluid (PICF) in peri-implantitis patients.
Detailed description
The aim of this study was to evaluate the relationship between TREM-1, MMP-8 and TIMP-1 levels in peri-implant crevicular fluid (PICF) in patients with peri-implantitis, and the correlation of these markers with clinical periodontal parameters.
Study design
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Target follow-up
- 12 Months
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Peri-implantitis | – | Other: Collection of PICF samplesPeri-implantitis is defined as bleeding on probing, suppuration, increased probing depth, clinical attachment loss, and radiographic bone loss |
| Peri-implant Health | – | Other: Collection of PICF samplesPeri-implant health is characterized by the absence of bleeding on probing, erythema, swelling, and suppuration in the peri-implant region |
Who may qualify
- Ages
- 18 to 70 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- All patients had at least one implant, and this implant had been in place for at least one year since the implant-supported prosthesis was made.
Key inclusion criteria (2 listed)
- Systemically healthy
- Pregnancy or lactation
Key exclusion criteria (4 listed)
- osteoporosis
- rheumatoid arthritis
- autoimmune disease
- diabetes
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Collection of PICF samplesTREM-1, MMP-8 and TIPM-1 levels reseach in PICF samples | Other | Peri-implant Health, Peri-implantitis |
Primary outcome
TREM-1, MMP-8 and TIMP-1 levels in PICF samples
Time frame: 1 month
TREM-1, MMP-8, and TIMP-1 levels in PICF samples were measured by ELISA method
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Feb 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Periimplantitis
Not yet recruiting
Effect of Customized Versus Stock Healing Abutments on Peri-Implant Soft Tissue
Peri-Implantitis
RecruitingObservational study
Evaluation of 25(OH)D3 and LL-37 Levels in Periimplant Sulcus Fluid
Peri Implantitis, Peri Implant Mucositis
Not yet recruitingObservational study
Diagnostic Accuracy of Large Language Models for Peri-Implant Marginal Bone Loss on Panoramic Radiographs
Peri-implantitis, Alveolar Bone Loss
RecruitingObservational study
Access to Probing and Peri-implant Diseases
Peri-implantitis, Peri-implant Bone Loss
Not yet recruitingObservational study
ATR-FTIR and Raman Spectroscopy of Peri-Implant Crevicular Fluid in Peri-Implantitis
Peri-Implantitis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Periimplantitis, run by Aydin Adnan Menderes University at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 9 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
TREM-1, MMP-8 and TIMP-1 levels in PICF samples (time frame: 1 month). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Feb 2026.